apimostinel IV (GATE-202) / AbbVie, Gate Neurosciences - LARVOL DELTA

Apimostinel + Automated Neurocognitive Training for Depression (clinicaltrials.gov) - P2 | N=150 | Recruiting | Sponsor: Rebecca Price | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Apimostinel + Automated Neurocognitive Training for Depression (clinicaltrials.gov) - P2 | N=150 | Not yet recruiting | Sponsor: Rebecca Price | Initiation date: Sep 2024 ➔ Jan 2025

Trial initiation date • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Apimostinel + Automated Neurocognitive Training for Depression (clinicaltrials.gov) - P2 | N=150 | Not yet recruiting | Sponsor: Rebecca Price | Trial completion date: Dec 2028 ➔ Dec 2029 | Initiation date: Jun 2024 ➔ Sep 2024 | Trial primary completion date: Dec 2028 ➔ Mar 2029

Trial completion date • Trial initiation date • Trial primary completion date • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

A Phase 1 Safety, Pharmacokinetics (PK) and Quantitative Electroencephalography (qEEG) Pharmacodynamics Study of Single and Multiple Ascending Doses of Intravenous Apimostinel Compared with Placebo in Healthy Volunteers (ASCP 2024) - "Learning Objectives The potential use of apimostinel in treating mood disorders. The use of quantitative electroencephalography to choose drug dose for clinical trials."

Clinical • P1 data • PK/PD data • CNS Disorders • Depression • Major Depressive Disorder • Mental Retardation • Mood Disorders • Pain • Psychiatry • Substance Abuse

Apimostinel + Automated Neurocognitive Training for Depression (clinicaltrials.gov) - P2 | N=150 | Not yet recruiting | Sponsor: Rebecca Price

New P2 trial • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Apimostinel, A Novel Nmdar Modulator with Rapid-Acting, Sustained Effects and Favorable Drug-Like Properties: Preclinical Studies (ASCP 2024) - "Background: NMDA receptor (NMDAR) modulation is an emerging rapid-acting pharmacological mechanism for treating neuropsychiatric disease, with recent FDA approvals of Spravato® and Auvelity®... Apimostinel is a novel NMDAR modulator that enhances activation of GRIN2A and GRIN2B-containg recombinant receptors. It demonstrating rapid and sustained single-dose enhancement of plasticity, with superior safety versus NMDAR antagonists like ketamine. Repeat low dose apimostinel produces an optimal effect on metaplasticity and alpha power."

Preclinical • CNS Disorders • Cognitive Disorders • Depression • Mental Retardation • Psychiatry • GRIN2A • GRIN2B

Multiple Ascending Dose and Electroencephalography Trial of GATE-202 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=40 | Completed | Sponsor: Gate Neurosciences, Inc | Recruiting ➔ Completed

Trial completion • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Multiple Ascending Dose and Electroencephalography Trial of GATE-202 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: Gate Neurosciences, Inc | Active, not recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Multiple Ascending Dose and Electroencephalography Trial of GATE-202 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=40 | Active, not recruiting | Sponsor: Gate Neurosciences, Inc

New P1 trial • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry